Neuberger Berman Group
AKRO

Neuberger Berman Group’s Akero Therapeutics AKRO Stock Holding History

Neuberger Berman Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,112
Closed -$219K – 2034
2025
Q2 		$219K Buy
+4,112
New +$187K ﹤0.01% 1858

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Neuberger Berman Group's AKRO Position: Q3 2025 in Review

Neuberger Berman Group sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 4,112 shares — an estimated $219K sold.

Neuberger Berman Group first reported a position in AKRO in Q2 2025 and held it in 1 quarter. The position peaked at $219K in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Neuberger Berman Group reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 4,112 Akero Therapeutics shares in Q3 2025, an estimated $219K.
  • Neuberger Berman Group first reported a position in Akero Therapeutics in Q2 2025 and held it in 1 quarter.
  • Neuberger Berman Group's Akero Therapeutics position peaked at $219K in Q2 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Neuberger Berman Group's 13F filing for Q3 2025, filed 12 Nov 2025.